"Uniting Science, Technology, and Talent to Get Ahead of Disease Together"
Table of Contents
1. Company Snapshot
🌍 Headquarters: London, UK | 🌐 Global Presence: 95 countries
📅 Founded: 2000 (via merger) | 🏦 Public: NYSE/LSE: GSK
👥 Employees: 70,000+ | 🔬 R&D Hubs: UK, US, Belgium
💻 Careers: GSK Careers
2. Mission, Vision & Values
🧬 Mission:
“To unite science, technology and talent to get ahead of disease together”
👁️ Vision:
“A world where people can do more, feel better, live longer”
🌟 Core Values:
- Patient Focus
- Transparency
- Respect for People
Culture: 3.9/5 Glassdoor | “Science-driven with global impact”
3. Key Leadership
| Role | Name | Leadership Style |
|---|---|---|
| CEO | Emma Walmsley | Transformational Leader |
| CSO | Tony Wood | Pharma Innovator |
4. Key Milestones
2015: HIV division ViiV Healthcare formed
2019: Consumer health split (Haleon)
2022: FDA approval for RSV vaccine
2023:
- FDA approval for Jemperli (cancer)
- ₹8,000cr India investment announced
5. Business Model & Position
💰 Revenue Streams:
- 60% Specialty Medicines
- 25% Vaccines
- 15% General Medicines
🆚 Key Competitors:
| Company | Differentiator |
|---|---|
| Pfizer | Larger vaccine portfolio |
| AstraZeneca | Stronger oncology pipeline |
6. Industry Trends & Challenges
📈 Opportunities:
- RSV vaccine market leadership
- HIV treatment innovations
- Emerging markets growth
⚠️ Challenges:
- Zantac litigation impacts
- Pipeline gaps in diabetes
7. Financial Health (2023)
| Metric | Value |
|---|---|
| Revenue | £30.3B |
| R&D Spend | £5.2B |
| Operating Margin | 23.6% |
8. SWOT Analysis
💪 Strengths:
- World’s #1 vaccine company (by volume)
- Strong HIV franchise (ViiV)
📉 Weaknesses:
- Consumer health spin-off impact
- Limited US market penetration
🌱 Opportunities:
- RSV vaccine Arexvy rollout
- India/China market expansion
⚠️ Threats:
- Patent expirations (2025-27)
- mRNA competition in vaccines
9. Recent Developments
🔬 Innovations:
- First-ever RSV vaccine for older adults
- 10 new Phase III starts in 2023
🌍 Global:
- £1B UK manufacturing investment
- India R&D center expansion
10. Interview Toolkit
Must-Know:
- CEO’s “Get Ahead” strategy
- ViiV Healthcare structure
Smart Questions:
“How is GSK maintaining HIV leadership amid generics?”
11. Conclusion
GSK transforms global health through:
🔹 Vaccine leadership (30+ vaccines)
🔹 HIV treatment breakthroughs
🔹 Science-first culture